Compare Stocks → Elon Musk: THIS will be bigger than Tesla (From Paradigm Press) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDigital Media StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare ShareLink copied to clipboard. NASDAQ:COGTNASDAQ:DNTHNASDAQ:PHARNASDAQ:SIGA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOGTCogent Biosciences$8.43-6.1%$7.51$3.67▼$13.36$805.54M1.61.27 million shs1.03 million shsDNTHDianthus Therapeutics$26.00-3.6%$23.57$6.58▼$33.77$763.07M1.83145,067 shs272,224 shsPHARPharming Group$8.60$9.46$7.67▼$16.71$579.16M0.186,943 shs12,485 shsSIGASIGA Technologies$6.67-11.7%$8.22$4.22▼$10.83$474.39M0.94459,706 shs1.15 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOGTCogent Biosciences0.00%+0.42%+12.78%+19.50%-34.44%DNTHDianthus Therapeutics0.00%+29.16%-0.95%-7.31%+2,599,999,900.00%PHARPharming Group+6.83%+1.90%-9.95%-25.14%-28.98%SIGASIGA Technologies0.00%-13.15%-15.57%-9.00%+16.00%Musk’s new company could top a trillion? (Ad)The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840. Click here to see the details because there’s not much time to prepare.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCOGTCogent Biosciences0.679 of 5 stars3.40.00.00.02.70.00.6DNTHDianthus Therapeutics1.6553 of 5 stars4.60.00.00.02.21.70.0PHARPharming Group1.755 of 5 stars3.53.00.00.03.10.00.6SIGASIGA Technologies0.1457 of 5 stars0.01.00.00.02.20.81.3Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOGTCogent Biosciences2.71Moderate Buy$14.6774.09% UpsideDNTHDianthus Therapeutics3.14Buy$42.8364.74% UpsidePHARPharming Group3.00Buy$37.00330.23% UpsideSIGASIGA TechnologiesN/AN/AN/AN/ACurrent Analyst RatingsLatest SIGA, DNTH, COGT, and PHAR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2024DNTHDianthus TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/31/2024PHARPharming GroupHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$37.00 ➝ $37.005/24/2024COGTCogent BiosciencesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$10.00 ➝ $10.005/16/2024DNTHDianthus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$40.005/13/2024COGTCogent BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$19.005/10/2024DNTHDianthus TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$33.00 ➝ $38.005/8/2024COGTCogent BiosciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.004/18/2024DNTHDianthus TherapeuticsRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$34.00 ➝ $51.003/22/2024DNTHDianthus TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$22.00 ➝ $39.003/22/2024DNTHDianthus TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$24.00 ➝ $33.00(Data available from 6/16/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOGTCogent BiosciencesN/AN/AN/AN/A$2.30 per shareN/ADNTHDianthus Therapeutics$2.83M269.65N/AN/A$11.40 per share2.28PHARPharming Group$245.32M2.36$0.10 per share88.23$3.26 per share2.64SIGASIGA Technologies$139.92M3.39$0.97 per share6.91$2.77 per share2.41Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOGTCogent Biosciences-$192.41M-$2.48N/AN/AN/AN/A-91.56%-55.20%8/13/2024 (Estimated)DNTHDianthus Therapeutics-$43.56M-$5.83N/AN/AN/AN/A-20.82%-19.86%8/1/2024 (Estimated)PHARPharming Group-$10.55M-$0.16N/A43.00N/A-4.01%-4.61%-2.18%8/1/2024 (Estimated)SIGASIGA Technologies$68.07M$1.106.066.23N/A50.48%51.97%39.51%8/13/2024 (Estimated)Latest SIGA, DNTH, COGT, and PHAR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2024Q1 2024DNTHDianthus Therapeutics-$0.43-$0.54-$0.11-$0.54$0.48 million$0.87 million5/8/2024Q1 2024PHARPharming Group$0.01-$0.19-$0.20-$0.19$68.43 million$55.59 million5/7/2024Q1 2024COGTCogent Biosciences-$0.51-$0.62-$0.11-$0.62N/AN/A5/7/2024Q1 2024SIGASIGA TechnologiesN/A$0.14+$0.14$0.14N/A$25.43 million3/21/2024Q4 2023DNTHDianthus Therapeutics-$1.11-$0.71+$0.40-$0.71$0.73 million$0.46 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOGTCogent BiosciencesN/AN/AN/AN/AN/ADNTHDianthus TherapeuticsN/AN/AN/AN/AN/APHARPharming GroupN/AN/AN/AN/AN/ASIGASIGA TechnologiesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOGTCogent BiosciencesN/A12.0512.05DNTHDianthus TherapeuticsN/A42.5242.52PHARPharming GroupN/A1.431.16SIGASIGA TechnologiesN/A3.052.19OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOGTCogent BiosciencesN/ADNTHDianthus Therapeutics47.53%PHARPharming Group0.03%SIGASIGA Technologies55.40%Insider OwnershipCompanyInsider OwnershipCOGTCogent Biosciences5.92%DNTHDianthus Therapeutics16.56%PHARPharming Group2.07%SIGASIGA Technologies1.54%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCOGTCogent Biosciences16495.61 million89.95 millionOptionableDNTHDianthus Therapeutics5329.35 million24.49 millionNo DataPHARPharming Group38267.34 million65.95 millionNot OptionableSIGASIGA Technologies4571.12 million70.03 millionOptionableSIGA, DNTH, COGT, and PHAR HeadlinesRecent News About These CompaniesJune 14 at 2:01 PM | stocknews.com3 Small-Cap Stocks With Big PotentialJune 13 at 3:40 AM | americanbankingnews.comSIGA Technologies Sees Unusually High Options Volume (NASDAQ:SIGA)June 13 at 3:40 AM | marketbeat.comInvestors Buy High Volume of SIGA Technologies Call Options (NASDAQ:SIGA)June 12, 2024 | seekingalpha.comSIGA Technologies: BARDA Contract Renewal Required To Sustain Recent Momentum (Rating Downgrade)June 5, 2024 | marketbeat.comGeneral American Investors Co. Inc. Has $4.44 Million Stake in SIGA Technologies, Inc. (NASDAQ:SIGA)June 4, 2024 | marketbeat.comCampbell & CO Investment Adviser LLC Acquires 179,388 Shares of SIGA Technologies, Inc. (NASDAQ:SIGA)May 31, 2024 | marketbeat.comFirst Wilshire Securities Management Inc. Raises Stock Position in SIGA Technologies, Inc. (NASDAQ:SIGA)May 31, 2024 | marketbeat.comSIGA Technologies (NASDAQ:SIGA) Shares Gap Down to $7.44May 30, 2024 | marketbeat.comSIGA Technologies Target of Unusually High Options Trading (NASDAQ:SIGA)May 29, 2024 | investing.comSIGA Tech (SIGA) Earnings Dates & ReportsMay 29, 2024 | msn.comLos sudafricanos votan en elecciones cruciales, el presidente dice no tener dudas de su victoriaMay 29, 2024 | pharmiweb.comBiodefense Market Anticipates Strong Growth to USD 36.8 Billion | Market.usMay 27, 2024 | msn.comSIGA Director-General visits Kumasi Abattoir, pledges support for managementMay 27, 2024 | ghanaweb.comSIGA Director-General pays historic visit to Kumasi AbattoirMay 27, 2024 | myjoyonline.comSIGA Director-General visits Kumasi AbattoirMay 20, 2024 | marketbeat.comSIGA Technologies (NASDAQ:SIGA) Shares Gap Down to $7.61May 17, 2024 | zacks.comNew Strong Buy Stocks for May 17thMay 11, 2024 | bovnews.comThe market value of SIGA Technologies Inc (SIGA) Stock is expected to soar in the coming monthsMay 10, 2024 | zacks.comIs Siga Technologies (SIGA) Stock Undervalued Right Now?May 10, 2024 | finance.yahoo.comSIGA Technologies First Quarter 2024 Earnings: EPS: US$0.14 (vs US$0.013 loss in 1Q 2023)May 8, 2024 | finance.yahoo.comSIGA Technologies, Inc. (NASDAQ:SIGA) Q1 2024 Earnings Call TranscriptNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCogent BiosciencesNASDAQ:COGTCogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.Dianthus TherapeuticsNASDAQ:DNTHDianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.Pharming GroupNASDAQ:PHARPharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.SIGA TechnologiesNASDAQ:SIGASIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.